Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cells.
D000256:Adenoviridae / Q000235:genetics*; D002455:Cell Division; D004815:Epidermal Growth Factor / Q000378:metabolism; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D005822:Genetic Vectors; D006801:Humans; D008297:Male; D010766:Phosphorylation; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000532:radiotherapy; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D011836:Radiation Tolerance; D014161:Transduction, Genetic / Q000379:methods; D014407:Tumor Cells, Cultured
D004815:Epidermal Growth Factor; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases